Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Lifted by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 942.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 145,930 shares of the company's stock after acquiring an additional 131,934 shares during the period. Los Angeles Capital Management LLC owned approximately 0.32% of Pacira BioSciences worth $2,196,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PCRX. Allspring Global Investments Holdings LLC grew its holdings in Pacira BioSciences by 114.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 10,188 shares of the company's stock valued at $298,000 after purchasing an additional 5,433 shares in the last quarter. Texas Permanent School Fund Corp increased its holdings in Pacira BioSciences by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 40,642 shares of the company's stock worth $1,188,000 after purchasing an additional 543 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Pacira BioSciences in the 1st quarter valued at approximately $106,000. Inspire Investing LLC boosted its stake in shares of Pacira BioSciences by 5.9% during the 1st quarter. Inspire Investing LLC now owns 12,131 shares of the company's stock valued at $354,000 after buying an additional 675 shares during the last quarter. Finally, QRG Capital Management Inc. increased its stake in shares of Pacira BioSciences by 42.0% in the first quarter. QRG Capital Management Inc. now owns 22,708 shares of the company's stock worth $664,000 after buying an additional 6,721 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Price Performance

PCRX traded down $0.08 during trading on Thursday, reaching $16.37. The stock had a trading volume of 434,362 shares, compared to its average volume of 857,468. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $35.95. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock has a 50 day moving average of $15.72 and a two-hundred day moving average of $20.78. The firm has a market capitalization of $755.85 million, a price-to-earnings ratio of -8.30 and a beta of 0.82.

Analyst Ratings Changes

Several equities analysts have recently commented on PCRX shares. Piper Sandler cut shares of Pacira BioSciences from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $42.00 to $11.00 in a research report on Monday, August 12th. HC Wainwright dropped their price target on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating on the stock in a research report on Monday, August 12th. StockNews.com lowered shares of Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 12th. Royal Bank of Canada upped their price objective on Pacira BioSciences from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research note on Thursday, November 7th. Finally, Barclays lowered their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, Pacira BioSciences has an average rating of "Hold" and an average target price of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.